Clinical Trial: LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study

U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07556640) titled 'LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study' on April 17.

Brief Summary: In this study, the investigators will use LM-302 and S-1 plus intraperitoneal paclitaxel with or without Cadonilimab to treat Claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis.

Study Start Date: April 17

Study Type: INTERVENTIONAL

Condition: Gastric Cancer Stage IV Peritoneal Metastases From Gastric Cancer Gastric or Esophagogastric Juncti...